ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ALMR / insiders
PACB (44) CTKB (45) BRKR (54) TXG (59) ⌘ Pro Terminal →

Alamar Biosciences Inc. (ALMR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$28.94 -5.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.60

Alamar Biosciences Inc. (ALMR) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $2.12B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALMR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $28.94 (-5.42% 1D, market cap $2.12B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALMR compare to PACB and CTKB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $809.7M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M). Among the 5-stock peer group, ALMR leads on earnings multiple (N/A) while BRKR leads on capital efficiency (1.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALMR?
▼

Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $58.8M in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $28.60 (-1.17%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 101.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C
Cash (10)Whales (10)SEC (13)Macro (13)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
$42 Bull$29 Base$22 Bear
📬 FREE ALMR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALMR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY ALMR SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (24% of score)

FRED Regime × Technicals: 49% of 52W Range • RSI-14 at 50.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$23.52+19.7% Next Q
Q2 (-2Q)
50
Grade C-$28.16+13.4% Next Q
Q3 (-1Q)
52
Grade C-$31.93-9.4% Next Q
Current
55
Grade D+$28.94-0.5% Hist 90D α
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALMR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ALMR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($30.60) or 200D SMA ($27.00) invalidates the momentum regime and cuts Target Base ($28.55) toward Bear Floor ($22.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ALMR Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ALMR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ALMR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALMR)

  • ✓Walkthrough of ALMR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.80%▲ ASCENDING CHANNEL
2026-11-03O $34.04H $34.04L $28.94C $28.94VOL 740.1K
RES: $40.16SUP: $23.57SMA50: $30.60SMA200: $27.00
$41.06$35.04$29.02$23.00$16.98RES $40.16SUP $23.57$28.942026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALMR Butterfly Map → + Track ALMR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALMR)

Health Care Rank #204 of 1015 ⚔️ PACB vs ALMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALMR vs. PACB, CTKB, BRKR, TXG)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alamar Biosciences Inc. (ALMR) ranks #204 by composite RQD confidence (55/100, grade D+) and #245 by equity capitalization ($2.12B). Within this direct 5-issuer industry benchmark cohort, ALMR leads on earnings valuation at N/A trailing P/E, while BRKR leads on capital efficiency and profitability with 1.3% ROIC and 45.9% gross margin. TXG currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ALMR at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALMR ACTIVE
Alamar Biosciences Inc.
D+ 55/100 — — — -5.42% $2.12B Benchmark Subject
PACB
Pacific Biosciences of California Inc.
D 44/100 — 28.6% -35.0% -9.98% $809.7M /pacb-vs-almr →
CTKB
Cytek Biosciences Inc.
D 45/100 — 51.8% -12.7% -5.87% $796.8M /ctkb-vs-almr →
BRKR
Bruker Corporation
D+ 54/100 — 45.9% 1.3% -2.42% $8.70B /brkr-vs-almr →
TXG
10x Genomics Inc.
C- 59/100 — 69.1% -5.7% -12.09% $9.13B /txg-vs-almr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002104204 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alamar Biosciences Inc. (ALMR) reported GAAP revenue of $58.8M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ALMR closed FY2025 with $140.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $58.8M $0 — — $140.0M —

3. ALMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $28.94 (-5.42% 1D, market cap $2.12B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does ALMR compare to PACB and CTKB in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $809.7M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $796.8M). Among the 5-stock peer group, ALMR leads on earnings multiple (N/A) while BRKR leads on capital efficiency (1.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALMR?

Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $58.8M in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALMR trading relative to its 50-day, 200-day, and 52-week technical levels?

ALMR last traded at $28.94 (-5.42% on volume of 875,856 shares), positioning the stock -5.42% below its 50-day simple moving average ($30.60) and +7.19% above its 200-day simple moving average ($27.00). Across its 52-week range of $18.85 to $39.61, ALMR sits at the 48.6% percentile with a 14-day RSI of 50.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($25.32 to $32.56).

Direct Sub-Reports: ALMR RQD Cockpit ALMR 12M Forecast ALMR Earnings & Move ALMR Dividends & DRIP ALMR Insiders & 13F ALMR Whale Options ALMR Profit Sankey ALMR News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ALMR — Alamar Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alamar Biosciences Inc. (ALMR) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $28.94 (-5.42% 1D, market capitalization $2.12B).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alamar Biosciences Inc. (ALMR) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Its market capitalization is $2.4B. — details on specific products, customers, or revenue model. The profile and financials sections do not describe what the company sells, to whom, or how it earns revenue beyond the reported FY 2025 values of — in revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Alamar Biosciences Inc. (ALMR) reported $58.8M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $140.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 55/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $18.85 – $39.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The main second-order channel the source data identifies is liquidity: because the graph reports a 3.56x net liquidity beta, shifts in Fed balance sheet, Treasury General Account, and overnight RRP conditions could amplify ALMR's price moves relative to the broader market. Investors should watch whether liquidity conditions remain supportive, since the graph's bullish signal depends on them.

  • Key Question #1: Can ALMR sustain or expand its — operating margin and — ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $58.8M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ALMR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ALMR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alamar Biosciences Inc. (ALMR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALMR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALMR Bull vs. Bear Conversation Board — What's Your Call at $28.94?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALMR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ALMR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $35.50 (+16.0%)
📌 Pinned Debate

Per the Butterfly Supply-Chain Graph, ALMR carries a 96/100 macro tailwind score and a 3.56x net liquidity beta, with institutional acc

Picked up a starter position in ALMR in my $100K Virtual Cash book at $30.60. Per the Butterfly Supply-Chain Graph, ALMR carries a 96/100 macro tailwind score and a 3.56x net liquidity beta, with institutional accumulation scoring 16 of 20 in the RQD rating.. Trading inside a $18.85–$39.61 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Laboratory Analytical Instruments multiples expand this quarter.

SectorRotator 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $25.09 (-18.0%)
Spot @ $30.60

Per the SEC financials, FY 2025 revenue, operating income, and net income are each $0.0M, with ROIC and FCF yield both at 0%, leaving t

Here is the bear case nobody on the bull side wants to address on ALMR: Per the SEC financials, FY 2025 revenue, operating income, and net income are each $0.0M, with ROIC and FCF yield both at 0%, leaving the fundamental cash engine pillar at 10 of 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Laboratory Analytical Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%